RSS-Feed abonnieren
DOI: 10.1055/s-0044-1789276
Colorectal Carcinoma: Is There Any Correlation between Her2/neu Expression, Ki-67 Score, and Tumor Budding and Clinicopathological Parameters?—A Prospective Institution-Based Study
Abstract
Objectives
Colorectal cancer is one of the most frequent cancers worldwide and is still a major cause of cancer mortality. Her2/neu, Ki67 score, and tumor budding are independent prognostic factors in colorectal carcinomas. The objectives of the study were to evaluate Her2/neu expression, Ki67 score, and tumor budding index at invasive margin in colorectal carcinoma and find out their possible correlations with different clinicopathological factors.
Materials and Methods
An institution-based observational cross-sectional study was conducted for 18 months. Forty-one patients with histologically proven diagnosis of colorectal carcinoma were included. Histopathological and immunohistochemical analyses (Her2/neu and Ki-67) of each case were done.
Statistical Analysis
Data analysis was done using the SPSS software.
Results
A significant correlation was found between tumor budding status and pathological T stage, Dukes' and American Joint Committee on Cancer stages, and between tumor-infiltrating lymphocytes status and Ki-67 expression status (p < 0.05).
Conclusion
The prognostic importance of tumor budding in colorectal carcinoma is very clear. Considering the small sample size of the present study, the prognostic values of Her2/neu and Ki-67 are required to be explored further in larger cohorts in the future.
Publikationsverlauf
Eingereicht: 04. März 2024
Angenommen: 26. Juli 2024
Artikel online veröffentlicht:
27. August 2024
© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Ahmad R, Singh JK, Wunnava A, Al-Obeed O, Abdulla M, Srivastava SK. Emerging trends in colorectal cancer: dysregulated signaling pathways (Review). Int J Mol Med 2021; 47 (03) 14
- 2 Lavingia V, Gore AA. Time for colorectal cancer screening in India!. Indian J Cancer 2021; 58 (03) 315-316
- 3 Boxberg M, Jesinghaus M, Dorfner C. et al. Tumour budding activity and cell nest size determine patient outcome in oral squamous cell carcinoma: proposal for an adjusted grading system. Histopathology 2017; 70 (07) 1125-1137
- 4 Petrelli F, Pezzica E, Cabiddu M. et al. Tumour budding and survival in stage II colorectal cancer: a systematic review and pooled analysis. J Gastrointest Cancer 2015; 46 (03) 212-218
- 5 Gianni L, Dafni U, Gelber RD. et al; Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12 (03) 236-244
- 6 Wang XY, Zheng ZX, Sun Y. et al. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. World J Gastrointest Oncol 2019; 11 (04) 335-347
- 7 Melling N, Kowitz CM, Simon R. et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol 2016; 69 (03) 209-214
- 8 Roy P, Datta J, Roy M, Mallick I, Mohandas M. Reporting of tumor budding in colorectal adenocarcinomas using ×40 objective: a practical approach for resource constrained set-ups. Indian J Cancer 2017; 54 (04) 640-645
- 9 Klintrup K, Mäkinen JM, Kauppila S. et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41 (17) 2645-2654
- 10 Graham RP, Vierkant RA, Tillmans LS. et al. Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort. Am J Surg Pathol 2015; 39 (10) 1340-1346
- 11 Heidari Z, Mahmoudzadeh-Sagheb H, Jahantigh M, Charkhat Gorgich EA. Immunohistochemical expression of Ki67 and HER2 in colorectal cancer compared to adenomatous and normal samples. Int J Cancer Manag 2017; 10: 122-152
- 12 Farzand S, Siddique T, Saba K, Bukhari MH. Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system. World J Gastroenterol 2014; 20 (19) 5889-5896
- 13 Kilicarslan A, Dogan HT, Sungu N, Dogan M, Yalcin A, Dede DS. Association in colorectal carcinoma and clinicopathological features. Pol J Pathol 2018; 69: 143-149
- 14 Jakubowska K, Kisielewski W, Kańczuga-Koda L, Koda M, Famulski W. Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma. Oncol Lett 2017; 14 (06) 6421-6432
- 15 Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C. The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep 2020; 10 (01) 3360